Jefferies analyst David Stanton downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company’s annual results in August.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast reports Q1 Ryoncil gross revenue $13.2M
- Mesoblast Announces Cessation of Securities and Capital Adjustments
- Buy Rating for Mesoblast: FDA Alignment and Promising Revascor Data Drive Optimism
- Mesoblast gives update on Revascor accelerated approval, Ryoncil label extension
- MESO Earnings Report this Week: Is It a Buy, Ahead of Earnings?